1-3 of 3
Carter Anthony
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

Abraham M Varghese, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, Richard A Jones, Andy Rawstron, PhD, J Sheila, Paul Evans, Carter Anthony, Claire E. Dearden, MD, Estella Matutes, Andrew R. Pettitt, PhD, MRCPath, Daniel B. Kennedy, Sharon Barrans, Lisa Worrillow, Peter Hillmen, MBChB, FRCP, FRCPath, PhD
Journal: Blood
Blood (2010) 116 (21): 922.
https://doi.org/10.1182/blood.V116.21.922.922
Published: 2010
Journal Articles

Final Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group).

Hazem A. Sayala, MD, Paul Moreton, MD, Richard A. Jones, PhD, Andy C. Rawstron, PhD, Sheila J. O’Connor, PhD, Paul Evans, PhD, Carter Anthony, MsC, Claire Dearden, MD, Estella Matutes, MD, PhD, Andrew R. Pettitt, MD, PhD, Daniel B. Kennedy, MD, Peter Hillmen, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 34.
https://doi.org/10.1182/blood.V108.11.34.34
Published: 2006
Journal Articles

Interim Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group).

Hazem Sayala, MD, Paul Moreton, MD, Jones A. Richard, PhD, Rawstron C. Andy, PhD, O’Connor Sheila, PhD, Evans Paul, PhD, Carter Anthony, MSc, Dearden Claire, MD, Matutes Estella, MD, PhD, Pettitt R. Andrew, MD, PhD, Kennedy B. Daniel, MD, Hillmen Peter, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 2120.
https://doi.org/10.1182/blood.V106.11.2120.2120
Published: 2005